By Michael Doane The CEO of a small technology-based company with many groundbreaking patents in its field once asked me what the point was of obtaining patents when the company […]
IPPI Summer 2025 Progress Report
IPPI Spring 2025 Progress Report (March – May 2025) Navigation IPPI Hosted and Co-Hosted Events News & Speaking Engagements Scholarship & Other Writing Greetings from IPPI Research Professor & Executive […]
IPPI Cautions that Pharmaceutical Tariffs Would Harm Patients and U.S. Innovation Leadership
IPPI has submitted formal comments to the U.S. Department of Commerce regarding its Section 232 investigation of pharmaceutical imports, cautioning against imposing tariffs on medicines and their ingredients. In our […]
RESTORE, PERA and PREVAIL: Bills that fix problems with the patent system
By Kristen Jakobsen Osenga As the 118th Congress drew to a close at the end of 2024, there was a spate of intellectual property activity on Capitol Hill. I was […]
Announcing IPPI + IPPI Spring 2025 Progress Report
Navigation Announcing IPPI: The IP Policy Institute A Message from Faculty Chair Mark Schultz & Executive Director Joshua Kresh IPPI Spring Progress Report (December 2024-February 2025) IPPI Hosted and Co-Hosted […]
[Archived Post] C-IP2 Winter 2024 Progress Report (September-November 2024)
Greetings from C-IP2 Interim Executive Director Joshua A. Kresh Reflecting on this vibrant winter season at the Center for Intellectual Property x Innovation Policy, I am filled with gratitude and […]
[Archived Post] Panel on “SEP Current & Proposed Regulations” at C-IP2’s 2024 Annual Fall Conference
By Keith Mallinson It was my pleasure to participate in a panel session on “SEP Current & Proposed Regulations” last month at the George Mason University Antonin Scalia Law School […]
[Archived Post] Panelists at George Mason’s IP conference debate litigation funding
By Kristen Osenga I recently had the pleasure of participating in a panel on third-party litigation funding (TPLF), which was part of the Annual Fall Conference at George Mason University’s […]
[Archived Post] What the FTC Gets Wrong About the FDA’s Orange Book
By Emily Michiko Morris & Douglas Park The high cost of some pharmaceuticals is a complex issue, but the Federal Trade Commission’s (FTC’s) most recent criticism of pharmaceutical patents’ role […]
[Archived Post] Copyright and Tattoos: New Amicus Brief in Sedlik v. Von Drachenberg; Oct. 29 Virtual Clinic for Visual Artists
CIP2 congratulates the Arts & Entertainment Advocacy Clinic at Scalia Law, led by Professor Sandra Aistars, and Student Advocate Natalie Nachman, and supported by Counsel of Record Matt Hersh of […]